| PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans. | PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans.
Ichiki T, Ito T, Shiraishi S, Nakashima Y, Nakahara T, Oda Y., Free PMC Article | 10/10/2024 |
| Characterization of PRAME immunohistochemistry reveals lower expression in pediatric melanoma compared to adult melanoma. | Characterization of PRAME immunohistochemistry reveals lower expression in pediatric melanoma compared to adult melanoma.
Forchhammer S, Aebischer V, Lenders D, Seitz CM, Schroeder C, Liebmann A, Abele M, Wild H, Bien E, Krawczyk M, Schneider DT, Brecht IB, Flatz L, Hahn M. | 09/26/2024 |
| PReferentially Expressed Antigen in MElanoma Expression in Uterine and Ovarian Carcinosarcomas. | PReferentially Expressed Antigen in MElanoma Expression in Uterine and Ovarian Carcinosarcomas.
Alrohaibani A, Yu Y, Gao L, McLean KM, Hetts J, Saglam O. | 04/26/2024 |
| Targeting PRAME for acute myeloid leukemia therapy. | Targeting PRAME for acute myeloid leukemia therapy.
Yang J, Chen M, Ye J, Ma H., Free PMC Article | 04/24/2024 |
| PRAME induces genomic instability in uveal melanoma. | PRAME induces genomic instability in uveal melanoma.
Kurtenbach S, Sanchez MI, Kuznetsoff J, Rodriguez DA, Weich N, Dollar JJ, Cruz A, Kurtenbach S, Field MG, Durante MA, Decatur C, Sorouri M, Lai F, Yenisehirli G, Fang B, Shiekhattar R, Pelaez D, Correa ZM, Verdun RE, Harbour JW., Free PMC Article | 02/22/2024 |
| PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer. | PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.
Cassalia F, Danese A, Tudurachi I, Federico S, Zambello A, Guidotti A, Franceschin L, Bolzon A, Naldi L, Belloni Fortina A., Free PMC Article | 02/22/2024 |
| Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes. | Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.
Wakefield C, O'Keefe L, Heffron CCBB. | 12/15/2023 |
| Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort. | Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
Lamas NJ, Lassalle S, Martel A, Nahon-Estève S, Macocco A, Zahaf K, Lalvee S, Fayada J, Lespinet-Fabre V, Bordone O, Pedeutour F, Baillif S, Hofman P. | 11/30/2023 |
| Immunohistochemistry for PRAME in Dermatopathology. | Immunohistochemistry for PRAME in Dermatopathology.
Lezcano C, Jungbluth AA, Busam KJ., Free PMC Article | 11/1/2023 |
| PRAME and LEF1 in Combined Deep Penetrating Nevus and Combined Blue Nevus: Utility and Pitfalls. | PRAME and LEF1 in Combined Deep Penetrating Nevus and Combined Blue Nevus: Utility and Pitfalls.
Vanderbeck K, Rothrock AT, Cho WC, Nagarajan P, Aung PP, Hudgens C, Bassett RL, Ivan D, Prieto VG, Curry JL, Torres-Cabala CA., Free PMC Article | 07/25/2023 |
| Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma. | Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF, Oh KS, Alexis J. | 07/20/2023 |
| Quantitative expression evaluation of PRAME gene in osteosarcoma. | Quantitative expression evaluation of PRAME gene in osteosarcoma.
Kuruwitage Ishikawa AS, Tesser-Gamba F, Petrilli AS, de Seixas-Alves MT, Garcia-Filho RJ, de Toledo SRC. | 05/8/2023 |
| PRAME Expression in Mucosal Melanoma of the Head and Neck Region. | PRAME Expression in Mucosal Melanoma of the Head and Neck Region.
Ricci C, Altavilla MV, Corti B, Pasquini E, Presutti L, Baietti AM, Amorosa L, Balbi T, Baldovini C, Ambrosi F, Grillini M, D'Errico A, Fiorentino M, Foschini MP., Free PMC Article | 04/19/2023 |
| Staged Excision of Lentigo Maligna of the Head and Neck: Assessing Surgical Excision Margins With Melan A, SOX10, and PRAME Immunohistochemistry. | Staged Excision of Lentigo Maligna of the Head and Neck: Assessing Surgical Excision Margins With Melan A, SOX10, and PRAME Immunohistochemistry.
de Wet J, Plessis PJD, Schneider JW. | 02/4/2023 |
| The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas. | The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas.
See SHC, Smith SH, Finkelman BS, LaBoy C, Novo JE, Siziopikou KP, Blanco LZ Jr. | 02/4/2023 |
| Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients. | Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients.
Kumar N, Singh MK, Singh L, Lomi N, Meel R, Pushker N, Sen S, Kashyap S. | 01/14/2023 |
| PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall. | PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall.
Coppock JD, Gradecki SE, Mills AM. | 01/11/2023 |
| PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics. | PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics.
Chen YP, Zhang WW, Qiu YT, Ke LF, Chen H, Chen G. | 12/17/2022 |
| Identification of <i>Cdk8</i> and <i>Cdkn2d</i> as New Prame-Target Genes in 2C-like Embryonic Stem Cells. | Identification of Cdk8 and Cdkn2d as New Prame-Target Genes in 2C-like Embryonic Stem Cells.
Lucci V, De Marino E, Tagliaferri D, Amente S, Pollice A, Calabrò V, Vivo M, Falco G, Angrisano T., Free PMC Article | 11/12/2022 |
| Clinically unquestionable but histologically deceptive melanomas in acral skin grafts: PRAME confirms its role. | Clinically unquestionable but histologically deceptive melanomas in acral skin grafts: PRAME confirms its role.
Santandrea G, Valli R, Ragazzi M, Castagnetti F, Lai M, Longo C, Piana S. | 11/12/2022 |
| SOX2 and PRAME in the ""reprogramming"" of seminoma cells. | SOX2 and PRAME in the "reprogramming" of seminoma cells.
Orsatti A, Sirolli M, Ambrosi F, Franceschini T, Giunchi F, Franchini E, Grillini M, Massari F, Mollica V, Bianchi FM, Colecchia M, Fiorentino M, Ricci C. | 10/29/2022 |
| PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors. | PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
Kaczorowski M, Chłopek M, Kruczak A, Ryś J, Lasota J, Miettinen M., Free PMC Article | 10/22/2022 |
| PRAME Expression in Junctional Melanocytic Proliferations of the Conjunctiva: A Potential Biomarker for Primary Acquired Melanosis/Conjunctival Melanocytic Intraepithelial Lesions. | PRAME Expression in Junctional Melanocytic Proliferations of the Conjunctiva: A Potential Biomarker for Primary Acquired Melanosis/Conjunctival Melanocytic Intraepithelial Lesions.
Huang YY, Hrycaj SM, Chan MP, Stagner AM, Patel RM, Bresler SC. | 10/15/2022 |
| PRAME immunostain expression in sebaceous lesions, cutaneous carcinomas and adnexal structures. | PRAME immunostain expression in sebaceous lesions, cutaneous carcinomas and adnexal structures.
Ng JKM, Choi PCL, Chow C, Li JJX, Chan AWS, Cheung CMT, Ip ECC, Ng HK, To KF. | 10/1/2022 |
| PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer Analysis. | PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer Analysis.
Zhao Q, Zhang Z, Wu Y. | 07/23/2022 |